The article provides a comprehensive overview of recent advances in the treatment and prevention of Ebola virus disease (EBOD). EBOD, characterized by a high mortality rate, has primarily relied on supportive care since its discovery in 1976. However, following the devastating 2014-2016 outbreak in West Africa, significant efforts have been made to develop effective therapeutic agents. Two monoclonal antibodies, Ebanga and Immazeb, received FDA approval in 2020, marking a shift from supportive care. Additionally, multiple vaccines have been approved for EBOD prevention, with Ervebo being the first to receive FDA approval in 2019. The article also discusses the transmission and prevention of EBOD, the principles of supportive care, and the role of antimicrobial therapy. It highlights the ongoing research into new treatment modalities, including GP inhibitors, polymerase inhibitors, and combination therapies, as well as the development of broad-spectrum monoclonal antibodies. The conclusion emphasizes the need for further research to address remaining challenges, such as the high mortality rate and the selection of viral escape variants.The article provides a comprehensive overview of recent advances in the treatment and prevention of Ebola virus disease (EBOD). EBOD, characterized by a high mortality rate, has primarily relied on supportive care since its discovery in 1976. However, following the devastating 2014-2016 outbreak in West Africa, significant efforts have been made to develop effective therapeutic agents. Two monoclonal antibodies, Ebanga and Immazeb, received FDA approval in 2020, marking a shift from supportive care. Additionally, multiple vaccines have been approved for EBOD prevention, with Ervebo being the first to receive FDA approval in 2019. The article also discusses the transmission and prevention of EBOD, the principles of supportive care, and the role of antimicrobial therapy. It highlights the ongoing research into new treatment modalities, including GP inhibitors, polymerase inhibitors, and combination therapies, as well as the development of broad-spectrum monoclonal antibodies. The conclusion emphasizes the need for further research to address remaining challenges, such as the high mortality rate and the selection of viral escape variants.